When was eGenesis founded?

eGenesis was founded in 2015 and raised its 1st funding round 1 year after it was founded.

Where is eGenesis located?

eGenesis is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

How many employees does eGenesis have?

As of Sep 30, 2026, the latest employee count at eGenesis is 153.

Is eGenesis a funded company?

eGenesis is a funded company, having raised a total of $495M across 8 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Aug 22, 2016.

How much is eGenesis worth?

The latest valuation of eGenesis is $***** as of Sep 04, 2024.

When was the latest funding round of eGenesis?

eGenesis' latest funding was a $***** Series D round on Aug 25, 2026, with participation from 1 investor.

Where does eGenesis rank among its competitors?

eGenesis ranks 2nd amongst 123 active competitors, of which 59 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was eGenesis, which secured $14M in Aug, 2026.

Who are the top competitors of eGenesis?

eGenesis' top competitors include Beam Therapeutics, Mammoth and Scribe Therapeutics. Among them, eGenesis secured the most recent funding round in August, 2026.

eGenesis - 2026 Company Profile, Team, Funding & Competitors

eGenesis is a series D company based in Cambridge (United States), founded in 2015 by Luhan Yang. It operates as a Developer of a gene transplantation platform for humanizing pig cells. eGenesis has raised $495M in funding from investors like Polaris Partners, Lux Capital and Farallon Capital Management, with a current valuation of $*****. The company has 123 active competitors, including 59 funded and 13 that have exited. Its top competitors include companies like Beam Therapeutics, Mammoth and Scribe Therapeutics.

Company Details

Developer of a gene transplantation platform for humanizing pig cells. The company has developed a technology to humanize pig cells that will grow into human-compatible organs. These organs will be harvested in the donor pig and safely transplanted to human patients. The company's technology is based on the next-generation genome engineering toolset and CRISPR.

Website: egenesisbio.com
Social
Email ID: *****@egenesisbio.com
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2015

Location

Cambridge, United States

Stage

Series D

Total Funding

$495M in 8 rounds

Latest Funding Round

Series D, Aug 25, 2026, $*****

Post Money Valuation

$***** as on Sep 04, 2024

Investors

Polaris Partners & 32 more

Ranked

2^nd among 123 active competitors

Employee Count

153 as on Sep 30, 2026

Investment & Acquisitions

ICBiotec

Similar Companies

Beam Therapeutics & 138 more

View eGenesis' full profile

eGenesis is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Egenesis, Inc. CIN: 475370912 , United States, Active	Dec 31, 2014	-	100 (As on Dec 31, 2024)	-

eGenesis has raised a total funding of $495M over 8 rounds. Its first funding round was on Aug 22, 2016. Its latest funding round was a Series D round on Aug 25, 2026 for $*****. 1 investor participated in its latest round. eGenesis has 33 institutional investors.

Here is the list of recent funding rounds of eGenesis:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 25, 2026	1899453	Series D	9213935	5604914	7106650	8242308
Sep 04, 2024	2687936	Series D	2920677	2514877	1112989	Natco Pharma & 9 more
2024	1652	Series C	1594	8761	8520	b2venture

Access funding benchmarks and valuations. Sign up today!

View details of eGenesis's funding rounds and investors

The founders of eGenesis is Luhan Yang.

Here are the details of eGenesis' key team members:

Luhan Yang: Co-Founder of eGenesis.
Contact Info: 1 email address

View details of eGenesis's Founder profiles and Board Members

eGenesis' employee count trend

eGenesis has 153 employees as of Sep 26. Here is eGenesis's employee count trend over the years:

Uncover eGenesis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of eGenesis include Beam Therapeutics, Mammoth and Scribe Therapeutics. Here is the list of Top 10 competitors of eGenesis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Beam Therapeutics 2017, Cambridge (United States), Public	Developer of gene therapy using CRISPR base editing to treat diseases	$222M	Redmile Group, Cormorant-asset & 16 others	70/100
2nd	eGenesis 2015, Cambridge (United States), Series D	Developer of a gene transplantation platform for humanizing pig cells	$495M	SymBiosis, Monashee Investment Management ... & 31 others	65/100
3rd	Mammoth 2017, Brisbane (United States), Series D	Provider of molecular diagnostics platform by using CRISPR technology	$271M	Redmile Group, Decheng Capital & 34 others	65/100
4th	Scribe Therapeutics 2018, Alameda (United States), Public	Developer of a gene-editing platform using CRISPR technology	$120M	Avoro Capital, Andreessen Horowitz & 7 others	65/100
5th	Metagenomi 2016, Berkeley (United States), Public	Digital gene editing technologies for drug development	$376M	Humboldt Fund, RA Capital Management & 22 others	64/100
6th	Locus Biosciences 2015, Raleigh (United States), Series B	Developer of therapeutics for infectious disease and inflammatory indications	$67.3M	Artis Ventures, Illumina & 13 others	64/100
7th	Prime Medicine 2019, Cambridge (United States), Public	Developer of genetic therapies for a wide range of diseases	$315M	T. Rowe Price, Redmile Group & 10 others	63/100
8th	Tessera Therapeutics 2017, Cambridge (United States), Series C	Provider of new genome engineering technology for treating multiple diseases	$610M	T. Rowe Price, ADIA & 22 others	63/100
9th	Kytopen 2017, Cambridge (United States), Series B	Developer of gene delivery systems for cell therapy	$44.5M	Northpond Ventures, Horizons Ventures & 12 others	61/100
10th	Watchmaker Genomics 2018, Boulder (United States), Series A	Developer of gene-editing technology	$48.3M	Decheng Capital, Eclipse	60/100